NT-proBNP, IGF-I and survival in patients with chronic heart failure

Growth Hormone & IGF Research - Tập 17 - Trang 288-296 - 2007
Mario Petretta1, Annamaria Colao2, Celestino Sardu1, Franco Scopacasa3, Paolo Marzullo2, Rosario Pivonello2, Luca Fontanella1, Maurizio de Caterina3, Adriano de Simone1, Domenico Bonaduce1
1Department of Internal Medicine, Cardiology, Heart and Immunological Sciences, Section of Internal Medicine, University of Naples “Federico II”, Italy
2Department of Molecular and Clinical Endocrinology and Oncology, Section of Endocrinology, Italy
3Department of Biochemistry and Medical Biotechnology, Italy

Tài liệu tham khảo

Saetrum Opgaard, 2005, IGF-I is a matter of heart, Growth Horm. IGF Res., 15, 89, 10.1016/j.ghir.2005.02.002

Niebauer, 1998, Deficient insulin-like growth factor I in chronic heart failure predicts altered body composition, anabolic deficiency, cytokine and neurohormonal activation, J. Am. Coll. Cardiol., 32, 393, 10.1016/S0735-1097(98)00226-5

Lee, 1999, Changes of the insulin-like growth factor I system during acute myocardial infarction: implications on left ventricular remodeling, J. Clin. Endocrinol. Metab., 84, 1575, 10.1210/jc.84.5.1575

Vasan, 2003, Serum insulin-like growth factor I and risk for heart failure in elderly individuals without a previous myocardial infarction: the Framingham Heart Study, Ann. Intern. Med., 139, 642, 10.7326/0003-4819-139-8-200310210-00007

Anker, 2001, Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone, J. Am. Coll. Cardiol., 38, 443, 10.1016/S0735-1097(01)01385-7

Mancini, 1992, Contribution of skeletal muscle atrophy to exercise intolerance and altered muscle metabolism in heart failure, Circulation, 85, 1364, 10.1161/01.CIR.85.4.1364

Anker, 1997, Wasting as independent risk factor for mortality in chronic heart failure, Lancet, 349, 1050, 10.1016/S0140-6736(96)07015-8

Hambrecht, 2002, Reduction of insulin-like growth factor-I expression in the skeletal muscle of noncachectic patients with chronic heart failure, J. Am. Coll. Cardiol., 39, 1175, 10.1016/S0735-1097(02)01736-9

Doust, 2005, How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review, BMJ, 330, 1, 10.1136/bmj.330.7492.625

Wahr, 1983, Left ventricular volumes determined by two-dimensional echocardiography in a normal adult population, J. Am. Coll. Cardiol., 1, 863, 10.1016/S0735-1097(83)80200-9

Gustafsson, 2005, Diagnostic and prognostic performance of N-terminal ProBNP in primary care patients with suspected heart failure, J. Card. Fail., 11, S15, 10.1016/j.cardfail.2005.04.022

Januzzi, 2006, NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study, Eur. Heart. J., 27, 330, 10.1093/eurheartj/ehi631

Cowie, 1997, Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care, Lancet, 350, 1349, 10.1016/S0140-6736(97)06031-5

Dao, 2001, Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting, J. Am. Coll. Cardiol., 37, 379, 10.1016/S0735-1097(00)01156-6

Zaphiriou, 2005, The diagnostic accuracy of plasma BNP and NTproBNP in patients referred from primary care with suspected heart failure: results of the UK natriuretic peptide study, Eur. J. Heart. Fail., 7, 537, 10.1016/j.ejheart.2005.01.022

Troughton, 2000, Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations, Lancet, 355, 1126, 10.1016/S0140-6736(00)02060-2

Omland, 1996, Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide, Circulation, 93, 1963, 10.1161/01.CIR.93.11.1963

McDonagh, 2001, Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population, Heart, 86, 21, 10.1136/heart.86.1.21

Yu, 1999, Plasma brain natriuretic peptide – an independent predictor of cardiovascular mortality in acute heart failure, Eur J Heart Fail, 1, 59, 10.1016/S1388-9842(98)00010-5

Hülsmann, 2005, Incidence of normal values of natriuretic peptides in patients with chronic heart failure and impact on survival: a direct comparison of N-terminal atrial natriuretic peptide, N-terminal brain natriuretic peptide and brain natriuretic peptide, Eur. J. Heart Fail., 7, 552, 10.1016/j.ejheart.2004.12.001

Richards, 2001, Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group, J. Am. Coll. Cardiol., 37, 1781, 10.1016/S0735-1097(01)01269-4

Anker, 1997, Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia, Circulation, 96, 526, 10.1161/01.CIR.96.2.526

Mangieri, 1996, Changes in growth hormone/insulin-like growth factor-1 axis in patients with normal pituitary function and biventricular cardiac failure and hepatic stasis, Cardiologia, 41, 449

Kontoleon, 2003, Hormonal profile in patients with congestive heart failure, Int. J. Cardiol., 87, 179, 10.1016/S0167-5273(02)00212-7

Fazio, 1996, A preliminary study of growth hormone in the treatment of dilated cardiomyopathy, N. Engl. J. Med., 334, 809, 10.1056/NEJM199603283341301

Giustina, 1996, Impaired spontaneous growth hormone secretion in severe dilated cardiomyopathy, Am. Heart J., 131, 620, 10.1016/S0002-8703(96)90552-9

McAlister, 2004, Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study, Circulation, 109, 1004, 10.1161/01.CIR.0000116764.53225.A9

Hillege, 2000, Renal function, neurohormonal activation, and survival in patients with chronic heart failure, Circulation, 102, 203, 10.1161/01.CIR.102.2.203

Dries, 2000, The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction, J. Am. Coll. Cardiol., 35, 681, 10.1016/S0735-1097(99)00608-7

de Silva, 2006, Incidence of renal dysfunction over 6 months in patients with chronic heart failure due to left ventricular systolic dysfunction: contributing factors and relationship to prognosis, Eur. Heart J., 27, 569, 10.1093/eurheartj/ehi696

LeRoith, 1992, NIH conference. Insulin-like growth factors in health and disease, Ann. Intern. Med., 116, 854, 10.7326/0003-4819-116-10-854

Mangieri, 1994, Blood levels of somatotropic hormone in patients with various degrees of heart failure, G Ital. Cardiol., 24, 845

Asplin, 1989, Alterations in the pulsatile mode of growth hormone release in men and women with insulin-dependent diabetes mellitus, J. Clin. Endocrinol. Metab., 69, 239, 10.1210/jcem-69-2-239

Tonshoff, 1997, Derangements of the somatotropic hormone axis in chronic renal failure, Kidney Int. Suppl., 58, S106

Richmond, 2001, The insulin-like growth factor system in kidney diseases, Nephron, 89, 5, 10.1159/000046035

Thông tin
Thông tin xuất bản

Growth Hormone & IGF Research

Tập 17

288-296

Thông tin tác giả